Adult (over 18 years old) kidney transplant recipients with the recurrence IgAN Kidney transplant recipients Recurrent IgAN Recurrent glomerular disease Rituximab
Conditions
Interventions
Recurrent IgAN patients who received rituximab additive to conventional therapies for recurrent IgAN.,Recurrent IgAN patients who did received rituximab additive to conventional therapies for recurren
Treatment,Treatment
Rituximab additive to conventional therapies ,Conventional therapies
Sponsors
None listed
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Adult kidney transplant recipients age >18 years old with the recurrence of IgAN
Exclusion criteria
Exclusion criteria: Missing clinical and laboratory data Referring to another hospital Previous treatment with rituximab for any other conditions History of recurrent infection or recurrent bacterial infection unrelated to either rituximab or other treatments for recurrent IgA nephropathy Ongoing use of high-dose corticosteroids (equivalent to 10 mg/day prednisolone) Pregnancy Pre-existing significant systemic or severe illness with expected life- expectancy <6 months before the diagnosis of recurrent IgA nephropathy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Graft survival after diagnosis of the recurrence IgAN after diagnosis of the recurrence IgAN | — |
Secondary
| Measure | Time frame |
|---|---|
| Renal allograft function determined by estimated glomerular filtration rate at 12, 24, 36, 48, and 60 months after diagnosis of the recurrence IgAN,Proteinuria levels at 12, 24, 36, 48, and 60 months after diagnosis of the recurrence IgAN,Adverse effects of rituximab from the recurrence IgAN treatment. at 12, 24, 36, 48, and 60 months after diagnosis of the recurrence IgAN | — |
Countries
Thailand
Contacts
Public ContactWiwat Chancharoenthana
Faculty of Tropical Medicine, Mahidol University
Outcome results
None listed